Randomized Controlled Trial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 16, 2024; 12(2): 314-321
Published online Jan 16, 2024. doi: 10.12998/wjcc.v12.i2.314
Impact of continuous care on cardiac function in patients with lung cancer complicated by coronary heart disease
Ting Gao, Jin-Lan Luo, Pan Guo, Xi-Wen Hu, Xiao-Yan Wei, Yan Hu
Ting Gao, Division of Cardiovascular First Ward, Department of Internal Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, Hubei Province, China
Jin-Lan Luo, Department of Cardiovascular Medicine, Wuhan Wuchang Hospital, Wuhan 430063, Hubei Province, China
Pan Guo, Xi-Wen Hu, Xiao-Yan Wei, Cardiovascular Clinical Medical Center, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, Hubei Province, China
Yan Hu, Department of Second Thoracic Surgery, Hubei Cancer Hospital, Wuhan 430079, Hubei Province, China
Co-first authors: Ting Gao and Jin-Lan Luo.
Author contributions: Gao T and Luo JN designed the research; Guo P, Hu XW, Wei XY and Hu Y contributed new reagents/analytic tools; Guo P, Hu XW, Wei XY and Hu Y analyzed the data; Gao T and Luo JN wrote the paper. All authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript. Gao T and Luo JN contributed equally to this work as co-first authors equally to this work. The reasons for naming Gao T and Luo JN as co-first authors are threefold. First, the research was a collaborative effort, and the designation accurately reflects the distribution of responsibilities and burdens. This ensures effective communication and post-submission management, enhancing the paper's quality and reliability. Second, the team encompassed diverse expertise and skills, and the designation reflects this diversity, promoting comprehensive and in-depth examination, enriching readers' understanding. Third, Gao and Luo contributed equally throughout the research process. Their designation acknowledges equal contribution and teamwork spirit. We believe naming them co-first authors accurately reflects our team's collaborative spirit, equal contributions, and diversity.
Institutional review board statement: The study was reviewed and approved by the Hubei Cancer Hospital Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors declare no potential conflicting interests related to this paper.
Data sharing statement: Data generated from this investigation are available upon reasonable quest from the corresponding author.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Hu, Nurse, Department of Second Thoracic Surgery, Hubei Cancer Hospital, No. 116 Zhuodaoquan South Road, Hongshan District, Wuhan 430079, Hubei Province, China. yanyan663311@163.com
Received: November 3, 2023
Peer-review started: November 3, 2023
First decision: November 16, 2023
Revised: December 6, 2023
Accepted: December 28, 2023
Article in press: December 28, 2023
Published online: January 16, 2024
Abstract
BACKGROUND

Despite sharing similar pathogenic factors, cancer and coronary heart disease (CHD) occur in comparable populations at similar ages and possess similar susceptibility factors. Consequently, it is increasingly commonplace for patients to experience the simultaneous occurrence of cancer and CHD, a trend that is steadily rising.

AIM

To determine the impacts of continuing care on lung cancer patients with CHD following percutaneous coronary intervention (PCI).

METHODS

There were 94 lung cancer patients with CHD following PCI who were randomly assigned to the intervention group (n = 38) and the control group (n = 41). In the intervention group, continuing care was provided, while in the control group, routine care was provided. An evaluation of cardiac and pulmonary function, medication compliance, a 6-min walk test, and patient quality of life was performed.

RESULTS

Differences between the two groups were significant in left ventricular ejection fraction, 6-min walk test, oxygen uptake, quality of life and medication compliance (P < 0.05). In comparison with the control group, the enhancement in the intervention group was more significant. The intervention group had more patients with high medication compliance than the control group, with a statistically significant difference (P < 0.05).

CONCLUSION

After undergoing PCI, lung patients with CHD could benefit from continued care in terms of cardiac and pulmonary function, medications compliance, and quality of life.

Keywords: Lung cancer, Continuing care, Coronary heart disease, Percutaneous coronary intervention

Core Tip: Despite sharing similar pathogenic factors, cancer and coronary heart disease (CHD) occur in comparable populations at similar ages and possess similar susceptibility factors. Consequently, it is increasingly commonplace for patients to experience the simultaneous occurrence of cancer and CHD, a trend that is steadily rising. Our study is to determine the impacts of continuing care on lung cancer patients with CHD following percutaneous coronary intervention (PCI). After undergoing PCI, lung patients with CHD could benefit from continued care in terms of cardiac and pulmonary function, medications compliance, and quality of life.